<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768363</url>
  </required_header>
  <id_info>
    <org_study_id>PrTK04</org_study_id>
    <nct_id>NCT02768363</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)</brief_title>
  <official_title>A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candel Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Candel Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in&#xD;
      patients undergoing active surveillance for localized prostate cancer. ProstAtak® involves&#xD;
      the use of aglatimagene besadenovec (CAN-2409) to kill tumor cells and stimulate a cancer&#xD;
      vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's&#xD;
      immune system to detect and destroy cancer cells. ProstAtak® has been well tolerated in&#xD;
      previous trials in patients with prostate cancer and other tumor types. Biochemical,&#xD;
      pathologic and immune responses have been demonstrated in newly diagnosed and recurrent&#xD;
      prostate cancer. The hypothesis is that ProstAtak can lead to improvement in the clinical&#xD;
      outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak®&#xD;
      or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance&#xD;
      evaluations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Once all subjects have completed at least 3 years following randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (change in PSA)</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months then at least yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Health Related Quality of Life</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radical treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase.</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProstAtak®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aglatimagene besadenovec</intervention_name>
    <description>Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.</description>
    <arm_group_label>ProstAtak®</arm_group_label>
    <other_name>AdV-tk</other_name>
    <other_name>CAN-2409</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ProstAtak®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Patients choosing active surveillance&#xD;
&#xD;
          -  Patients meeting definition of NCCN low risk, intermediate risk OR patients having&#xD;
             only one NCCN high-risk feature&#xD;
&#xD;
               -  NCCN Low Risk is defined as having all of the following: PSA &lt; 10 ng/ml, Gleason&#xD;
                  ≤ 6, T1-T2a&#xD;
&#xD;
               -  NCCN Intermediate Risk is defined as having at least one of the following and no&#xD;
                  high risk features: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c&#xD;
&#xD;
               -  High Risk with a single high risk feature is defined as having only one of the&#xD;
                  following: PSA&gt;20 ng/ml, Gleason score 8-10, or T3a&#xD;
&#xD;
               -  Excluded are those in the following risk groups: High risk with more than 1 high&#xD;
                  risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1&#xD;
&#xD;
          -  Patients must be planning and medically able to tolerate multiple transrectal&#xD;
             ultrasound guided injections.&#xD;
&#xD;
          -  ECOG Performance status 0-2&#xD;
&#xD;
        Exclusion Criteria include:&#xD;
&#xD;
          -  Active liver disease, including known cirrhosis or active hepatitis&#xD;
&#xD;
          -  Patients on systemic corticosteroids (&gt;10 mg prednisone per day) or other&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          -  Known HIV+ patients&#xD;
&#xD;
          -  Regional lymph node involvement or distant metastases&#xD;
&#xD;
          -  Other current malignancy (except squamous or basal cell skin cancers)&#xD;
&#xD;
          -  Other serious co-morbid illness or compromised organ function that, in the opinion of&#xD;
             the investigator, would interfere with treatment or follow up&#xD;
&#xD;
          -  Prior treatment for prostate cancer except TURP. If prior TURP, patients must be&#xD;
             deemed able to receive prostate biopsy and multiple intra-prostatic injections by the&#xD;
             investigator&#xD;
&#xD;
          -  Patients taking 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride)&#xD;
&#xD;
          -  Patients who had or plan to use ADT or have history of an orchiectomy.&#xD;
&#xD;
          -  Patients who are planning to undergo radical treatment for prostate cancer within 12&#xD;
             months.&#xD;
&#xD;
          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Foothills Urology</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Louisiana Veterans Health Care System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Nevada Health Care System VA</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>North Hills</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY, PLLC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Urology, Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City VA Healthcare System</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Urology Insitute</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Urology</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network-Triangle Urological Group</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson Veterans Affairs Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio VA Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland Center</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Urology Specialists</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Tumor vaccine</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytotoxicity</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Active Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

